Kevin DeGeeter

- Xenetic Biosciences, Inc. priced an underwritten offering of **735,000 shares** of common stock at **$6.12 per share** on October 10, 2025.  **[1534525_0001683168-25-007528_xenetic_ex9901.htm:0]** **[1534525_0001683168-25-007528_xenetic_8k.htm:1]** 
- The offering is expected to generate approximately **$4.5 million** in gross proceeds and **$3.9 million** in net proceeds.  **[1534525_0001683168-25-007528_xenetic_ex9901.htm:0]** **[1534525_0001683168-25-007528_xenetic_8k.htm:1]** 
- The company intends to use the net proceeds for **working capital, general corporate purposes**, and the **advancement of its DNase technology**.  **[1534525_0001683168-25-007528_xenetic_8k.htm:1]** **[1534525_0001683168-25-007528_xenetic_ex9901.htm:1]** 
- The offering is expected to close on or about **October 14, 2025**.  **[1534525_0001683168-25-007528_xenetic_ex9901.htm:0]** **[1534525_0001683168-25-007528_xenetic_8k.htm:1]** 
- Canaccord Genuity LLC is acting as the **sole bookrunner** for the offering.  **[1534525_0001683168-25-007528_xenetic_ex9901.htm:1]**

Xenetic Biosciences (XBIO)